BLUE - Bluebird bio's chief medical officer to leave

bluebird bio (BLUE) has lost ~1.5% in the post-market trading after announcing the departure of its chief medical officer David Davidson with effect from April 16, 2021.However, following the exit, Dr. Davidson will serve as a consultant for six months, supporting the company’s late-stage development programs targeting genetic diseases particularly regulatory interactions for recently discovered safety events.The company recently ruled out any link between BB305 lentiviral vector and acute myeloid leukemia which forced it to halt two clinical trials in sickle cell disease.

For further details see:

Bluebird bio’s chief medical officer to leave